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TITLE
Hemodynamic Response to Device Titration in the Shunted Single Ventricle Circulation:
A Patient Cohort Modeling Study
ABSTRACT
Clinical outcomes of ventricular assist device (VAD) support for shunted single
ventricle patients trail the larger population due in part to the challenges in optimizing
VAD support and balancing systemic and pulmonary circulations. We sought to
understand the response to VAD titration in the shunted circulation using a lumpedparameter network modeling six patient-specific clinical cases. Hemodynamic data
from six patients (mean BSA=0.30m2) with a systemic-to-pulmonary shunt was used to
construct simulated cases of heart failure and hemodynamic response to increasing
VAD flow from 5 to 10 L/min/m2. With increasing VAD flow, the pulmonary arterial
pressure stayed relatively constant in 5 patient cases and increased in one patient case.
The mean VAD flow needed to attain an AVO2 of 30% was 6.5 +/- 1.2 L/min/m2, which
is higher than that in the equivalent non-shunted scenario due to the partial diversion of
flow to the pulmonary circulation. The hemodynamic responses to VAD support can
vary significantly between specific patient cases; therefore hemodynamic modeling may
help guide an individualized approach to perioperative VAD management in the shunted
single ventricle circulation and to understand the patients who may benefit the most
from VAD support.
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GLOSSARY
AVO2
BSA
CapO2
ConsO2
CO
Qp/Qs
Qp
Qs
RSUC
SaO2
SpvO2
SvO2
VAD

Arterial-venous O2 saturation difference
Body surface area
Blood O2 carrying capacity
O2 consumption
Cardiac output
Pulmonary-to-systemic flow ratio
Pulmonary blood flow
Systemic blood flow
Ventricular suction resistance
Arterial O2 saturation
Pulmonary vein O2 saturation
Venous O2 saturation
Ventricular assist device

Introduction
The number of children supported with ventricular assist devices (VADs), has
grown significantly over the last two decades. The percentage of children bridged to
transplant with a VAD has increased from 13% to 33%.1 Increased VAD utilization has
led to improved waitlist mortality and improved post-transplant outcomes when
compared to ECMO.2, 3
However, improvements in outcome due to increased VAD utilization are not
uniform across the population of children with heart failure. Patients < 1 year of age and
those with congenital heart disease are less likely to be bridged to transplant on a VAD
and only 5-6% of infants with congenital heart disease <1 year of age are bridged to
transplant with a VAD.1 Decreased device utilization in this cohort is likely driven by
early experiences with VAD therapy showing increased mortality in small children
(<10kg), especially those with congenital heart disease, where the mortality rate was
~70%.4 The mortality rate reached 100% for Stage 1 single ventricle patients supported
with the Berlin EXCOR.5
Subsequent maturation of the field, the use of alternate cannulation strategies,
and the use of paracorporeal continuous flow devices in select patients have resulted in
marked improvements in survival for small patients and those with congenital heart
disease.6, 7 While there have been significant improvements in survival, clinical
outcomes for patients with univentricular physiology continue to trail the larger overall
cohort. A recent analysis of the Pediatric Interagency Registry for Mechanical
Circulatory Support (PediMACS) found that 64% of Stage 1 patients achieved a positive
outcome. Adverse clinical outcomes are likely driven in part by the challenges in
balancing the systemic and pulmonary circulations in patients with shunted physiology,
and in understanding fundamental concepts including pump selection (size and type)
and patient management.5 Historically, individual centers have been reticent to
increase VAD flows due to concerns that increased cardiac output may result in
pulmonary over-circulation and by reports suggesting that the use of a large for body
surface area (BSA) EXCOR pump may contribute to stroke risk8 and inadequate VAD
filling.9 Unfortunately there is no significant literature regarding ramp studies in the
shunted circulation to help understand the hemodynamic effects of VAD titration and
help guide patient management. Recently, individual centers have reported successful
support in Pre-Glenn patients using a management strategy incorporating higher VAD
flows.10, 11 However, it is unclear whether this approach is broadly generalizable and
there is no concrete conviction across the clinical community for prescribing higher VAD
flows to shunted patients and if so the values generally needed to provide adequate
systemic blood flow without compromising respiratory status through overcirculation and
elevation of pulmonary artery pressures. Previous data using mathematical modeling
underscored the potential pitfalls of VAD support in the setting of shunted physiology,
however, those assumed a pre-specified device revolutions-per-minute setting and did
not examine the individual, potentially divergent, hemodynamics for a given patient.12
Thus, in this study, we employed patient-specific lumped-parameter physiology models
of VAD therapy to quantify the hemodynamic response to VAD titration in the systemicpulmonary shunted circulation.
Methods

The overall flow of the methods (Fig 1) involves creating patient-specific
computational models that describe VAD-supported heart failure scenarios. Using the
blood flow information from these simulation results, we computed O2 related
parameters for the simulated shunted scenarios, as well as for the trivial case if the
simulated patient had non-shunted circulations given the resulting CO in each simulated
scenario. Finally, we quantified the cardiac indices required to achieve specific levels of
oxygenation comparing between the shunted and non-shunted scenarios. The details
for each component of the methods are described in the sections below.
VAD Support Hemodynamic Simulations
The hemodynamics of patient-specific VAD support scenarios were simulated
according to our previous work.9 Briefly, we started with clinical measurements of six
systemic-pulmonary shunted single ventricle patients (age: 3-6 month, BSA: 0.26-0.34
m2) (Table S1) from the Great Ormond Street Hospital, Medical University of South
Carolina, and University of Michigan.13 Institutional review board study approval was
obtained for each clinical site with informed consent for data use obtained from the
participants’ legal guardians. For each patient, we tuned a lumped-parameter
physiology model based on the individual patient’s clinical measurements to create the
pre-support model.14, 15 Once tuning was complete, we set the ventricular contractility to
zero to simulate heart failure and connected a continuous flow VAD model between the
ventricle and the aorta to arrive at the VAD supported scenario (Fig 2). While in clinical
practice the outflow cannula could be attached to one of several locations near the
aorta, since the lumped-parameter model is a simplified representation of vasculature,
these locations each correspond to the aortic node as shown in Fig 2.
The lumped-parameter model formulation includes implementations that capture
ventricular suction, suction release, and negative ventricular pressure behaviors. The
ventricular suction is relevant to the ventricular collapse induced by a VAD if it attempts
to draw blood from the ventricle below its reference volume, resulting in a negative
pressure and collapse. When these suction events occur, tissue may be drawn into the
cannula or the septum may be drawn closer to the cannula, both of which can inhibit
blood flow.16 If complete flow obstruction occurs, the inflow cannula attaches to the
collapsed ventricular wall; in such a case a “pop off” pressure is needed to overcome
the negative cannula pressure and release the cannula from the wall. Finally, the
pressure-volume relationship of the ventricle has two different regimes depending on
whether ventricular pressure is positive or negative. All of these behaviors are captured
in our physiology model formulation.9
Due to the similar centrifugal designs of commercially available continuous flow
VADs, they would produce similar hemodynamics when generating the same pressure
outputs according to the device-specific HQ curves. We simulated a range of VAD
pressure outputs in each patient case resulting in a range of cardiac indexes depending
on the specific patient physiologies. For the purposes of the analyses in this study, the
blood flow serves as the independent variable affecting oxygen related parameters.
Results are reported across the spectrum of flow up-titration until suction-induced
ventricular collapse occur in the model (as in patients A and B) where the ventricular
suction resistance (RSUC) ≥0.04 mmHg.s/ml.
O2 Related Parameter Calculations

Based on the hemodynamic simulation results, we calculated arterial and venous
oxygen saturations for the systemic-to-pulmonary shunted circulation via the following
equations:
=
=

+
−

(1)
(2)

where Qp, Qs, CO, ConsO2, CapO2, SpvO2, SaO2, and SvO2 are mean values of
pulmonary blood flow, systemic blood flow, cardiac output, O2 consumption, blood O2
carrying capacity, pulmonary vein O2 saturation, arterial O2 saturation, and venous O2
saturation, respectively. SaO2 and SvO2 are the quantities to be solved. The blood flow
related parameters Qp, Qs, and CO are quantities available from the hemodynamic
simulation results. SpvO2 is assumed to be 97%. We estimated the value of CapO2 to
be 0.151 ml-O2/ml-blood based on previously published hemoglobin O2 carrying
capacity (1.31 ml-O2/gHb consistently across fetal to adult population) and hemoglobin
concentration in 3-month old infants (0.115 gHb/ml-blood).17, 18 Finally, we estimated
the value of ConsO2 using the regression model reported by Seckeler et al.8 for critically
ill children and adults with congenital heart defects; since this regression model
requires patient age and weight as inputs, we used the relationship between BSA and
weight in children to obtain the patient’s weight estimate from the BSA measurement
which is available in our clinical data.19
Finally, using the O2 Saturation results we calculated the oxygen delivery by
multiplying Qs by CapO2 and SaO2.
O2 Parameters for the Non-shunted Circulation
We calculated what the SvO2 and oxygen delivery would be if the simulated
patient cases had non-shunted circulations given the resulting CO in each simulated
scenario. In a non-shunted circulation, SaO2 is equaled to SpvO2, the oxygen delivery
is CO multiplied by CapO2 and SaO2, and SvO2 is solved from the equation
=

−

(3)

Surplus Cardiac Index
Comparing the shunted to the non-shunted scenario for each simulated patient,
we quantified the additional cardiac index required to achieve any specific level of
desired arterial-venous O2 saturation difference (AVO2). To perform this direct
comparison, we first mathematically quantified the cardiac index as a function of AVO2
by fitting a power equation to relate these two quantities using the simulation results
from each patient model; this resulted in a total of six functions (one for each simulated
patient) for the shunted scenario and six functions for the non-shunted scenario. We
then used these fitted functions to directly compute the difference between the cardiac
indexes for the shunted and non-shunted scenarios at different AVO2 levels and defined
the resulting quantity as the “Surplus Cardiac Index.”
Results

At any particular CI, the shunted circulation produced lower O2 delivery and
AVO2 than the non-shunted circulation (Fig 3). The increase in O2 delivery with
increasing CI, while linear in both cases, had a shallower slope for the shunted
compared to the non-shunted circulation (Fig 3A). The mean VAD flow needed to
achieve an AVO2 of at least 30% for the shunted-circulation was 6.5 L/min/m2, with a
standard deviation of 1.2 L/min/m2.
In terms of hemodynamics, the ratio of pulmonary to systemic flow (Qp/Qs)
slightly decreased with increasing CI in all patient cases (Fig 4A), while the pulmonary
arterial pressure stayed relatively constant with changing CI in 5 of the patients (Fig 4B).
One patient experienced sequential increases in pulmonary arterial pressure as VAD
flow was titrated.
To achieve any particular AVO2, the shunted circulation required a “surplus
cardiac index” (as defined in the Methods section) in all patient cases compared to the
non-shunted circulation (Fig 5). This surplus cardiac index is a function of the desired
AVO2. At 30% AVO2 the mean and standard deviation of the surplus cardiac index in
the six simulated patients was 3.07 and 1.16 L/min/m2, respectively.
Discussion
The early experiences supporting children with shunted single ventricle
physiology were poor;5 none of the patients with shunt physiology survived. These poor
outcomes were theorized to be driven by the difficulty in selecting an appropriate pump
size for patients with parallel circulation, prominent aortopulmonary blood flow, and the
challenge of anticoagulating neonates and infants due to developmental hemostasis.20
Since the initial reports, some strides have been made from adjustments in
hemodynamic support and anticoagulation management. The field has rapidly shifted
toward the use of paracorporeal continuous flow devices in order to offset some of the
concerns of selecting an appropriate pump size.7 There has also been a rapid shift
toward the use of direct thrombin inhibitors in infants and children supported with
paracorporeal VADs.21 While outcomes continue to trail those in patients with nonshunted physiology, survival has clearly improved over time as recent analysis of the
PediMACS data showed that 64% of shunted patients achieved a positive outcome.7
Despite these gains, questions remain about the ability to balance pulmonary blood flow
and oxygen delivery and there are no significant ramp studies to help inform
management.11 Thus, while the hemodynamic challenges inherent to the shunted
circulation have been known for decades, the quantifiable impact of VAD therapy on the
circulation has not been investigated.
In the current study, a lumped-parameter model assessed the interactions
between O2 delivery, VAD flow, pulmonary blood flow, systemic blood flow and
pulmonary arterial pressures to begin to quantify the impact of VAD therapy in shunted
physiology. The patient-specific simulations demonstrated that the hemodynamic
response to increasing VAD flows to ensure adequate oxygen delivery is variable and
patient-specific. This is notable for patient management in that it helps to define
plausible and expected device titration needs in the shunted circulation, but also
because it expands upon the previous work using lumped parameters models in the
shunted circulation. Previous modeling suggested a 40% increase in pulmonary artery
pressure with device implantation, however, it was unclear whether these results are

universal.22 The current study suggests this pulmonary artery pressure elevation is not
inevitable and that serial titration of the VAD with concomitant decreases in atrial
pressure may mitigate this effect in select patients.
In order to further inform patient management, we also compared the shunted
and non-shunted circulation. The O2 delivery increases with uptitrating VAD flow in the
shunted circulation, but at a shallower slope when compared to the non-shunted
circulation due to partial diversion of flow to the pulmonary vascular bed. The fact that
not all of the CI contributes to systemic flow (i.e. O2 delivery) in the shunted circulation
also results in higher AVO2 at any particular CI suggesting larger increments of device
uptitration will be needed in order to effectively increase systemic oxygen delivery.
Compared to the non-shunted circulation, a surplus VAD flow of 3.07 L/min/m2 on
average was needed to offset pulmonary blood flow and achieve similar tissue oxygen
delivery at an AVO2 of 30%; however, there was a 40% standard-deviation of this
surplus flow among patient cases. The scale of the variation is notable and suggests
that patient-specific estimates of flow based on physiologic parameters or diagnostics
(including MRI or existing catheterization) would be valuable especially when selecting
cannulae and pump sizes. The shallower slope of pulmonary artery pressure associated
with VAD titration in the shunted circulation is also notable. Providers are often hesitant
to increase flow in larger increments due to concerns that this will disproportionately
increase pulmonary artery pressure;12, 22 the current study suggests conservative
uptitration will provide inadequate systemic oxygen delivery and potentially also result in
higher pulmonary artery pressures given the majority of patients saw a decrement in
atrial pressures (and subsequently pulmonary artery pressures) as the devices are
uptitrated. This point is likely fundamental to understanding which shunted patients may
benefit from VAD support. In patients where elevated common atrial pressure due to
ventricular dysfunction drives elevation of pulmonary artery pressure, and who have an
appropriately restrictive shunt, VAD support provides a means to improve oxygen
delivery and decrease pulmonary artery pressure. The ability to drop common atrial
pressures while improving systemic output is likely different from the non-VAD
supported shunted patient where initiation of inotropic support may increase systemic
oxygen delivery, but does so at the expense of increases in common atrial pressure due
to residual systolic dysfunction, diastolic dysfunction, and systemic valve regurgitation.
Thus, the current modeling approach may help providers accommodate for both
the increased flow needs at time of implant and understand the hemodynamic effects of
titration. This approach may also help to understand the long term hemodynamic
implications of patient growth on support. While the variation reported may make
device titration appear a daunting task, it underscores the utility in using mathematical
models to help guide initial management. It also suggests centers should have a low
threshold to consider hemodynamic ramp studies for any patient not progressing
clinically.
The initial modeling work by Di Molfetta et al. demonstrated that while VAD
support improves systemic blood flow, this may come at the expense of increasing
pulmonary arterial pressure by 40% or more.12 This clinical scenario is well described
and has led centers to optimize shunt size and medical management (i.e. low systemic
vascular resistance state) in order to balance Qp/Qs in an individual patient.23, 24 The
current study finds that increases in pulmonary arterial pressure are not universal with

up-titration of VAD flow, but also confirms the well-described challenges of VAD support
in patients with a minimally restrictive shunt where Qp/Qs is high. We suspect the latter
situation is what is occurring in the case of patient F (Fig 4). Patient F has the highest
Qp/Qs, implying that their shunt is large for the body size, this then allows more of the
aortic pressure to translate to the pulmonary artery. The increases in VAD flow needed
to ensure adequate systemic blood flow resulted in adverse changes in pulmonary
artery pressure (>15 mmHg). In situations that mimic the hemodynamics of patient F,
alternate methods such as maintaining a low systemic vascular resistance may be
needed to optimize hemodynamics. Further studies are needed to help identify patients
likely to respond in a similar manner (e.g. those with larger shunt to body size ratios)
and to understand the impact that clinical management approaches such as lowering
the systemic vascular resistance may have on hemodynamic support. Patient-specific
modeling may help define the circumstances where adequate hemodynamics will be
difficult to achieve even with optimal device titration and medical therapy. This is
consistent with the literature in the two ventricle circulation where the device
optimization has become an important part of clinical care due to the discrepant
physiologic responses to device titration.25, 26
Limitations
Our study presents six patient-specific scenarios as example cases to illustrate
the hemodynamic response at different levels of VAD support. These cases do not
represent the comprehensive combinations of physiologic parameters that can
potentially occur in a patient. Even though the full range of patient scenarios (e.g. high
vascular resistance state, significant collateral burden, etc) were not specifically
included as part of the current simulation and analyses, these circumstances can be
captured and modeled using the method described and this work is ongoing. This
further emphasizes the importance of patient-specific assessment and the unique needs
of each patient. While there was some variation in the characteristics of the patients in
the current study, the hemodynamic profile of shunted patients listed for transplant may
be different. The clinical data used to construct the model did not originate from
patients with heart failure, and heart failure was simulated via adjustments of the
contractility parameter in the computational model. The fact that the model assumes no
inherent ventricular contribution is worth noting when interpreting the results as any
residual ventricular ejection would alter the cardiac output. Aortopulmonary collateral
flow, shunt anatomy, hematocrit variations, and pulmonary artery anatomy also have
marked effects on hemodynamics and oxygen delivery; we have not accounted for
these in the current study and are working to understand the potential impact of these
factors on patient hemodynamics. Lastly, future modeling studies can benefit from
incorporating cardiovascular feedback mechanisms to capture the patient's autoregulation response to surgery, VAD titration, and hemodynamic manipulation.27
Conclusions
Clinical management of VAD patients involves the unique challenge of needing
to determine appropriate device titration. Due to the partial diversion of flow to the
pulmonary circulation, the mean “surplus VAD flow” in order to achieve systemic oxygen
delivery similar to that in the non-shunted circulation was >3 L/min/m2. This needed
additional flow replenishes the flow diverted by the shunt and therefore can be
determined via an estimation of pulmonary blood flow. An increase in VAD flow does

not necessarily result in dramatic increases in pulmonary arterial pressure and may
allow decreases in common atrial pressure and improved systemic oxygen delivery.
These results suggest that for shunted patients on VAD support, prescribing higher
(compared to non-shunted patients of similar body sizes) VAD flows can be considered
as a potentially beneficial therapeutic option. Understanding the quantities and range of
VAD outputs needed to effectively support patients with a shunted circulation is integral
to surgical planning and to improving support outcomes in this patient population.
Larger studies describing the hemodynamics effects across the range of patient
hemodynamic and anatomic profiles will be valuable to further understand the potential
hemodynamic effects of VAD support in the shunted circulation.
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FIGURES
Fig 1. Overall flow diagram of the study methods.

Fig 2. Circuit model of the VAD-supported systemic-to-pulmonary shunted circulation.
Labels “AO” and “RSUC” denote the aortic node and the ventricular suction resistance,
respectively. Detailed model formulation is described in reference.9

Fig 3. O2 related parameters versus cardiac index for six patient-specific simulated
cases. Solid (also black) and dotted (also red) lines represent the systemic-topulmonary shunted, and non-shunted (normal), scenario, respectively.

Fig 4. Hemodynamic parameters versus cardiac index for six patient-specific simulated
cases of systemic-to-pulmonary shunting circulation.

Fig 5. The surplus cardiac index reveals in each patient-specific simulated case the
additional flow required to achieve the same AVO2 for the systemic-to-pulmonary
shunted scenario relative to the non-shunted (normal) scenario.

